Kiromic BioPharma Balance Sheet Health
Financial Health criteria checks 2/6
Kiromic BioPharma has a total shareholder equity of $-9.1M and total debt of $14.0M, which brings its debt-to-equity ratio to -153.5%. Its total assets and total liabilities are $12.2M and $21.3M respectively.
Key information
-153.5%
Debt to equity ratio
US$14.00m
Debt
Interest coverage ratio | n/a |
Cash | US$3.20m |
Equity | -US$9.12m |
Total liabilities | US$21.29m |
Total assets | US$12.17m |
Recent financial health updates
Recent updates
Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year
Oct 06Dr. Leonardo Mirandola is the new Chief Scientific Officer of Kiromic biopharma
Jul 12Kiromic expands in-house cell therapy manufacturing facility, names new COO
Jun 07Kiromic BioPharma files two IND applications for CAR-T therapy in cancer
Dec 17Kiromic BioPharma reports Q3 results
Nov 30Financial Position Analysis
Short Term Liabilities: KRBP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: KRBP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: KRBP has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: KRBP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KRBP has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: KRBP is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.